The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up.
 
Takashi Kojima
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Covidien; EA Pharma; Japan Esophageal Society; Japanese Society of Pharmaceutical Health Care and Sciences; Kyowa Kirin International; Liang Yi Hui Healthcare; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; CMIC; NPT Co.,Ltd.
Research Funding - Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); BeiGene (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takashi Ogata
Speakers' Bureau - Bristol Myers Squibb Foundation; MSD; Ono Pharmaceutical
 
Ryu Ishihara
No Relationships to Disclose
 
Hiroki Hara
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; Miyarisan pharmaceutical; MSD; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan
Research Funding - Abbvie (Inst); ALX Oncology (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Henlius (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Tianmo Sun
Employment - BeiGene
 
Sheng Xu
Employment - BeiGene Beijing
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)